Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO-FA: Mitochondrial biomarkers in Friedreich's ataxia patients treated with omaveloxolone
2025-523881-26-00Phase 4Authorised
- Sponsor
- Motol University Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of omaveloxolone in Friedreich ataxia (FA) (2 arms), sponsored by Motol University Hospital. Primary endpoint: Change in mitochondrial biomarkers over time in omaveloxolone-treated FA patients. Planned start Mar 2026; status: authorised.
02
Drugs
omaveloxolone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2025-523881-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523881-26-00.